IQVIA MARKET PROGNOSIS
Market Prognosis is a strategic market forecasting publication that provides unparalleled insights into the key issues affecting the local pharmaceutical and healthcare industries.
The Market Prognosis country-level forecasts for 2024-2028 are now available.
In our latest reports, discover:
- How Japan's promising new FY2024 drug pricing reforms will address new product launch lags in the market and ensure stability in the drug supply chain
- The impact of France’s reformed early access (accès précoce) system over the first two and a half years after its implementation
- The implications of efforts to limit the National Insurance Scheme's drug expenditure, including tendering for certain outpatient reimbursed (blue prescription) drugs, on Norway’s pharmaceutical market
- Why the WHO’s maturity level three (ML3) recognition of the national medicine regulator will impact registrational timelines in Turkey
- How Lula’s state-led health development programs will strengthen domestic drug production in Brazil, whilst domestic manufacturers’ focus on lower priced strategic drugs, including generics, will curb market growth
- How the introduction of ‘One ID Card, Treat Anywhere’ policy will improve system efficiency and enhance access to treatment to boost Thailand’s pharmaceutical market
- Why retail pharmacies’ leverage of technology will contribute to Saudi Arabia’s primary care strategy
The 49 individual country reports and PowerPoint summary slides are now available via the IQVIA Syndicated Analytics Library. Please note that the regional summaries in Excel will be available by 5 April, and the regional summaries in PowerBI by 12 April.
Market Prognosis forecasting expertise can help you to understand the key drivers and constraints of the pharmaceutical markets for better strategic planning and decision making.
Submit your details below to learn more.
Copyright © 2024 IQVIA Holdings Inc. and its affiliates. All rights reserved. Privacy Statement
